Who Paid My Doc
Eduardo Vazquez
Pain Medicine El Paso, TX Medical Doctor
NPI 1225283211 CMS profile 191262
3215 Gateway Blvd W, Ste 100, El Paso, TX 79903
General payments
$19,451
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Eduardo Vazquez of El Paso, TX is reported in the CMS Open Payments database as having received $19,451 across 697 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 90th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,483 | 43 | |
| 2024 | General | $3,310 | 64 | |
| 2023 | General | $2,371 | 111 | |
| 2022 | General | $3,172 | 124 | |
| 2021 | General | $4,358 | 153 | |
| 2020 | General | $2,263 | 103 | |
| 2019 | General | $2,494 | 99 |
Beside peers
- Eduardo Vazquez
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Eduardo Vazquez were reported at $1,483. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Eduardo Vazquez | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,494 | $498 | $126–$1,682 | $163 |
| 2020 | $2,263 | $284 | $80–$910 | $114 |
| 2021 | $4,358 | $399 | $112–$1,219 | $132 |
| 2022 | $3,172 | $455 | $137–$1,484 | $149 |
| 2023 | $2,371 | $484 | $128–$1,495 | $160 |
| 2024 | $3,310 | $498 | $131–$1,540 | $164 |
| 2025 | $1,483 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,313
Drug cost
$31,022
Branded share of claims
41.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 360 | $8,042 | |
| Pregabalin | Generic | 223 | $6,163 | |
| Naloxone Hcl | Generic | 70 | $4,412 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 141 | $2,386 | |
| Buprenorphine | Generic | 11 | $2,123 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 39 | $1,080 | |
| Lidocaine | Generic | 11 | $955 | |
| Duloxetine Hcl | Generic | 22 | $953 | |
| Diclofenac Sodium | Generic | 15 | $772 | |
| Gabapentin | Generic | 59 | $765 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 72 billing codesPaid by Medicare
$206,372
Medicare patients
456
Services billed
9,344
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 45% | |
| Depression | 32% | |
| Chronic kidney disease | 29% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 20% | |
| COPD | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 | Office | 17 | 4,704 | $1,890 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 153 | 1,703 | $149 |
| Injection, fentanyl citrate, 0.1 mg J3010 | Office | 23 | 27 | $20 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 26 | 71 | $8 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
697 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pain Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.